The renin–angiotensin–aldosterone system (RAAS) plays a pivotal role in regulating blood pressure, volume, and electrolytes. The final product of RAAS cascade is angiotensin II, which exerts diverse biological activities via binding to one of three known receptor types, with different binding consequences. Despite the success with conventional strategies to limit angiotensin II production and action, these agents promote a reflex rise in plasma renin activity, which is thought to be associated with an increased incidence of cardiovascular events. Several renin inhibitors have been synthesized in order to counteract deleterious consequences of renin activity and RAAS activation; aliskiren is the first of these new non-peptide direct renin inhibitors to be approved for the treatment of hypertension. The paper reviews pharmacokinetics of aliskiren and its role in hypertension, with particular regard to those studies that compared clinical efficacy of aliskiren in comparison and in addition to other antihypertensive drug strategies.
KeidarSKaplanMGamliel-LazarovichA. ACE2 of the heart: From angiotensin I to angiotensin (1–7). Cardiovasc Res2007; 73(3): 463–469.
2.
UrataHKinoshitaAMisonoKSBumpusFMHusainA. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem1990; 265(36): 22348–22357.
3.
RoksAJMBuikemaHPintoYMvan GilstWH. The renin–angiotensin system and vascular function: the role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. Heart Vessels1997; suppl 12: 119–124.
TouyzRM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep2003; 5(2): 155–164.
6.
SchellingPFischerHGantenD. Angiotensin and cell growth: a link to cardiovascular hypertrophy?J Hypertens1991; 9(1): 3–15.
7.
TouyzRMTabetFSchiffrinEL. Redox-dependent signaling by angiotensin II and vascular remodeling in hypertension. Clin Exp Pharmacol Physiol2003; 30(11): 860–866.
8.
VaughanDE. Angiotensin, fibrinolysis, and vascular homeostasis. Am J Cardiol2001; 87(8A): 18C–24C.
9.
LijnenPJPetrovVVFagardRH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst2001; 2(2): 117–122.
10.
MasakiHKuriharaTYamakiAInomataNNozawaYMoriY. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest1998; 101(3): 527–535.
11.
ChakiSInagamiT. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma Neuro-2A cells. Biochem Biophys Res Commun1992; 182(1): 388–394.
12.
WrightJWHardingJW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev1994; 18(1): 21–53.
13.
KramárEAHardingJWWrightJW. Angiotensin II- and IV-induced changes in cerebral blood flow: Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept1997; 68(2): 131–138.
14.
VickersCHalesPKaushikVDickLGavinJTangJ. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem2002; 277(17): 14838–14843.
15.
SchindlerCBramlagePKirchWFerrarioCM. Role of the vasodilator peptide angiotensin-(1–7) in cardiovascular drug therapy. Vasc Health Risk Manag2007; 3(1): 125–137.
16.
FerrarioCMBrosnihanKBDizDIJaiswalNKhoslaMCMilstedA. Angiotensin-(1–7): a new hormone of the angiotensin system. Hypertension1991; 18(5 Suppl.): III126–III133.
17.
CampbellDJWoodwardMChalmersJPColmanSAJenkinsAJKempBE. Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation2005; 112(1): 110–116.
18.
OliverJA. Receptor-mediated actions of renin and prorenin. Kidney Int2006; 69(1): 13–15.
19.
NguyenGDelarueFBurckleCBouzhirLGillerTSraerJD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest2002; 109(11): 1417–1427.
20.
DanserAHvan KatsJPAdmiraalPJDerkxFHLamersJMVerdouwPD. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension1994; 24(1): 37–48.
WoodJMMaibaumJRahuelJGrütterMGCohenNCRasettiV. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun2003; 308(4): 698–705.
23.
WaldmeierFGlaenzelUWirzBObererLSchmidDSeiberlingM. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos2007; 35(8): 1418–1428.
24.
WoodJMSchnellCRCuminFMenardJWebbRL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens2005; 23(2): 417–426.
25.
AziziMWebbRNussbergerJHollenbergNK. Renin inhibition with aliskiren: where are we now, and where are we going?J Hypertens2006; 24(2): 243–256.
26.
AllikmetsK. Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. Vasc Health Risk Manag2007; 3(6): 809–815.
27.
VaidyanathanSJarugulaVDieterichHAHowardDDoleWP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet2008; 47(8): 515–531.
HuPBartlettMKaranRSJiangJZhangSZhangJ. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. Clin Drug Investig2010; 30(4): 221–228.
30.
ZhaoCVaidyanathanSYehCMMaboudianMArmin DieterichH. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet2006; 45(11): 1125–1134.
31.
VaidyanathanSReynoldsCYehCMBizotMNDieterichHAHowardD. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol2007; 47(4): 453–460.
32.
BuczkoWHermanowiczJM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep2008; 60(5): 623–631.
33.
GradmanAHSchmiederRELinsRLNussbergerJChiangYBedigianMP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation2005; 111(8): 1012–1018.
34.
WoodJMMaibaumJRahuelJGrütterMGCohenNCRasettiV. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun2003; 308(4): 698–705.
35.
ImanishiTTsujiokaHIkejimaHKuroiATakaradaSKitabataH. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension2008; 52(3): 563–572.
36.
LastraGHabibiJWhaley-ConnellATManriqueCHaydenMRRehmerJPatelKFerrarioCSowersJR. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology2009; 150(6): 2561–2568.
37.
FischerRDechendRQadriFMarkovicMFeldtSHerseF. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension2008; 51(2): 540–546.
38.
ChrysantSGMurrayAVHoppeUCDattaniDPatelSHsuH. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin2008; 24(4): 1039–1047.
39.
PuigJGSchunkertHTaylorAABoyeSJinJKeefeDL. Evaluation of the dose–response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin Ther2009; 31(12): 2839–2850.
40.
StraussMHHallAS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation2006; 114(8): 838–854.
41.
SealeyJELaraghJH. Aliskiren, the first renin inhibitor for treating hypertension: reactive rennin secretion may limit its effectiveness. Am J Hypertens2007; 20(5): 587–597.
42.
OparilSYarowsSAPatelSFangHZhangJSatlinA. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet2007; 370(9583): 221–229.
43.
IchiharaAKaneshiroYTakemitsuTSakodaMNakagawaTNishiyamaA. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol2006; 17(9): 2495–2503.
44.
IchiharaASuzukiFNakagawaTKaneshiroYTakemitsuTSakodaM. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol2006; 17(7): 1950–1961.
45.
IchiharaAKaneshiroYTakemitsuTSakodaMSuzukiFNakagawaT. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension2006; 47(5): 894–900.
46.
Botero-VelezMCurtisJJWarnockDG. Liddle’s syndrome revisited ⊟ a disorder of sodium reabsorption in the distal tubule. New Eng J Med1994; 330(3): 178–181.
47.
YusufSSleightPPogueJBoschJDaviesRDagenaisG. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Eng J Med2000; 342(3): 145–153.
48.
JuliusSWeberMAKjeldsenSEMcInnesGTZanchettiABrunnerHR. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension2006; 48(3): 385–391.
49.
OhBHMitchellJHerronJRChungJKhanMKeefeDL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol2007; 49(11): 1157–1163.
50.
KushiroTItakuraHAboYGotouHTeraoSKeefeDL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res2006; 29(12): 997–1005.
51.
KushiroTItakuraHAboYGotouHTeraoSKeefeDL. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res2009; 32(3): 169–175.
52.
SchmiederREPhilippTGuerediagaJGorostidiMSmithBWeissbachN. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. A 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation2009; 119(3): 417–425.
53.
BlumensteinMRomaszkoJCalderónAAndersenKIbramGLiuZ. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin2009; 25(4): 903–910.
54.
LittlejohnTW3rdTrenkwalderPHollandersGZhaoYLiaoW. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin2009; 25(4): 951–959.
55.
DrummondWMungerMARafique EssopMMaboudianMKhanMKeefeDL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens2007; 9(10): 742–750.
56.
DietzRDechendRYuCMBhedaMFordJPrescottMF. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst2008; 9(3): 163–175.
57.
NussbergerJWuerznerGJensenCBrunnerHR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension2002; 39(1): e1–e8.
58.
AndersenKWeinbergerMHEganBConstanceCMAliMAJinJ. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens2008; 26(3): 589–599.
59.
VerdecchiaPCalvoCMockelVKeelingLSatlinA. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press2007; 16(6): 381–391.
60.
StantonAJensenCNussbergerJO’BrienE. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension2003; 42(6): 1137–1143.
61.
PalatiniPJungWShlyakhtoEBothaJBushCKeefeDL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens2009; 24(2): 93–103.
62.
AziziMMènardJBisseryAGuyenneTTBura-RivièreAVaidyanathanS. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II–renin feedback interruption. J Am Soc Nephrol2004; 15(12): 3126–3133.
63.
YarowsSAOparilSPatelSFangHZhangJ. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther2008; 25(12): 1288–1302.
64.
MusiniVMFortinPMBassettKWrightJM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev2008; (4: CD007066–CD007066.
65.
VillamilAChrysantSGCalhounDSchoberBHsuHMatrisciano-DimichinoL. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens2007; 25(1): 217–226.
66.
UresinYTaylorAKiloCTschopeDSantonastasoMIbramG. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens2006; 24(Suppl 4): S82–S82.
67.
O’BrienEBartonJNussbergerJMulcahyDJensenCDickerP. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension2007; 49(2): 276–284.
68.
PoolJLSchmiederREAziziMAldigierJCJanuszewiczAZidekW. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens2007; 20(1): 11–20.
69.
JordanJEngeliSBoyeSWLe BretonSKeefeDL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension2007; 49(5): 1047–1055.
70.
GeigerHBarrancoEGorostidiMTaylorAZhangXXiangZ. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens2009; 11(6): 324–332.
71.
NussbergerJAubertJFBouzoureneKPellegrinMHayozDMazzolaiL. Renin inhibition by aliskiren prevents atherosclerosis progression comparison with irbesartan, atenolol, and amlodipine. Hypertension2008; 51(5): 1306–1311.
PilzBShagdarsurenEWellnerMFiebelerADechendRGratzeP. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension2005; 46(3): 569–576.
74.
KellyDJZhangYMoeGNaikGGilbertRE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia2007; 50(11): 2398–2404.
75.
WestermannDRiadALettauORoksASavvatisKBecherPM. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension2008; 52(6): 1068–1075.
76.
McMurrayJJPittBLatiniRMaggioniAPSolomonSDKeefeDL. Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail2008; 1(1): 17–24.
77.
FisherNDanserAHJNussbergerJDoleWPHollenbergNK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation2008; 117(25): 3199–3205.
78.
PerssonFRossingPSchjoedtKJJuhlTTarnowLStehouwerCDSchalkwijkC. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int2008; 73(12): 1419–1425.
79.
SeedAGardnerRMcMurrayJHillierCMurdochDMacFadyenR. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail2007; 9(11): 1120–1127.
80.
Recio-MayoralAKaskiJCMcMurrayJJHorowitzJvan VeldhuisenDJRemmeWJ. Clinical trials update from the European society of cardiology congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther2007; 21(6): 459–465.
81.
PoolJL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm2007; 13(8 Suppl B): 21–33.
82.
SolomonSDAppelbaumEManningWJVermaABerglundTLukashevichVfor the Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation2009; 119(4): 530–537.
83.
ParvingHHPerssonFLewisJBLewisEJHollenbergNKStudy InvestigatorsAVOID. Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Eng J Med2008; 358(23): 2433–2446.
84.
VerdecchiaPAngeliFMazzottaGGentileGReboldiG. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag2008; 4(5): 971–981.
85.
RiccioniGVitulanoND’OrazioNBellocciF. Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension. Adv Ther2009; 26(7): 700–710.
86.
SeverPSGradmanAHAziziM. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst2009; 10(2): 65–76.
GrahamIAtarDBorch-JohnsenKBoysenGBurellGCifkovaR. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil2007; 14(Suppl 2): S1–S113.
89.
VerdecchiaPAngeliFReboldiG. Good news from aliskiren?Clin Med Ther2009; 1: 999–1002.
